Non-Muscle Invasive Bladder Cancer Pipeline Insights and Companies | DelveInsight

November 03 21:50 2021
Non-Muscle Invasive Bladder Cancer Pipeline Insights and Companies | DelveInsight

DelveInsight’s “Non-Muscle Invasive Bladder Cancer Pipeline Insight, 2021” highlights the details around Non-Muscle Invasive Bladder Cancer. Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder.

 

Non-Muscle Invasive Bladder Cancer Overview

Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. Bladder cancer is the 6th most common cancer in the United States. Nearly 81,000 people will be diagnosed in the United States with bladder cancer in 2020. Bladder cancer is more common in males than females.

 

Download Sample Report- Non-Muscle Invasive Bladder Cancer Pipeline Report

 

Non Muscle Invasive Bladder Cancer Companies

  • UroGen Pharma
  • CG Oncolgy
  • Sasanlimab
  • Sesen Bio
  • Theralase Technologies

 

Non-Muscle Invasive Bladder Cancer Pipeline: Risk Factors

Research shows that people with certain risk factors are more likely to develop bladder cancer. These include:

• Smoking – cigarette smokers are up to three times more likely than nonsmokers to develop bladder cancer

• Older age – most people with bladder cancer are over 60, and the risk increases with age

• Being male – men are three to four times more likely than women to develop bladder cancer

 

Non-Muscle Invasive Bladder Cancer Pipeline: Symptoms

Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:

• Hematuria (blood in the urine) – the most common symptom, often without pain

• Frequent and urgent urination

• Pain when urine passes

• Pain in lower abdomen

• Back pain

 

Non Muscle Invasive Bladder Cancer Pipeline: Diagnosis

The diagnosis of bladder cancer ultimately depends on cystoscopic examination of the bladder and histological evaluation of the resected tissue although about 4% of cases will be found incidentally, usually during imaging to investigate non-urological symptoms. However, the detection rate for white light cystoscopy (WLC) can be limited (as low as 60%). Strong evidence has shown that enhanced visualization methods using (hexyl aminolevulinate (HAL)-photodynamic diagnosis (PDD) or narrow band imaging (NBI)) may improve tumor detection and early recurrence. Blue light cystoscopy (BLC) or PDD requires preoperative intravesical instillation of hexaminolevulinate (HAL), a photosensitizer that preferentially accumulates in neoplastic cells. Under blue light, red fluorescence is emitted by neoplastic cells.

 

Non-Muscle Invasive Bladder Cancer Treatment

The main treatments for when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, immunotherapy and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Most people with non-muscle-invasive bladder cancer have an operation called transurethral resection of bladder tumour (TURBT). This is done during a cystoscopy under a general anaesthetic. It takes 15–40 minutes, and does not involve any external cuts to the body. Immunotherapy uses substances that encourage the body’s own natural defenses (immune system) to fight disease. Bacillus Calmette-Guérin (BCG) is a vaccine that was originally used to treat tuberculosis. It can also stimulate a person’s immune system to stop or delay bladder cancer coming back or becoming invasive.

 

More InformationNon-Muscle Invasive Bladder Cancer Pipeline Insights

 

Table of content

  1. Introduction
  2. Executive Summary
  3. Non Muscle Invasive Bladder Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non Muscle Invasive Bladder Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. UGN-102: UroGen Pharma
  9. Mid Stage Products (Phase II)
  10. TLD 1433: Theralase Technologies
  11. Early Stage Products (Phase I)
  12. VAX-014: Vaxiion Therapeutics
  13. Preclinical/Discovery Stage Products
  14. Vesibax: Prokarium
  15. Inactive Products
  16. Non Muscle Invasive Bladder Cancer Key Companies
  17. Non Muscle Invasive Bladder Cancer Key Products
  18. Non Muscle Invasive Bladder Cancer- Unmet Needs
  19. Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
  20. Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
  21. Non Muscle Invasive Bladder Cancer Analyst Views
  22. Appendix

 

About DelveInsight

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

 

Contact Us

Yash

[email protected]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

view more articles

About Article Author